Table 1.
Target | Therapeutic Agent | Carcinoma | Trial Drug Design | Reg. Nr. |
---|---|---|---|---|
mTORC1 | everolimus | EC | Everolimus (RAD001) and Letrozole or Hormonal Therapy | NCT02228681 |
Atypical hyperplasia or FIGO stage IA EC | Levonorgestrel-Releasing Intrauterine System with or without Everolimus | NCT02397083 | ||
OC, EC, CC | Patients with alterations in PIK3CA, PIK3R1, AKT1, AKT2, mTOR, RICTOR, RAPTOR genes, or with TSC1, TSC2 or PTEN loss for maintenance therapy | NCT02029001 | ||
everolimus temsirolimus |
Advanced OC | Vemurafenib in Combination with Everolimus or Temsirolimus | NCT01596140 | |
sirolimus | Stage II-IV OC | The effects of TRICOM vaccine with sirolimus | NCT01536054 | |
mTORC1/2 | Vistusertib (AZD2014) |
HR positive EC | AZD2014 and anastrozole vs. anastrozole alone |
NCT02730923 |
Sapanisertib MLN0128 |
EC and other solid tumors | Single experimental arm: bevacizumab and MLN0128 | NCT02142803 | |
Sapanisertib MLN0128 |
EC, OC | Patients with mTOR mutation receive sapanisertib as a single experimental arm | NCT02465060 | |
AKT inhibitors | miransertib ARQ 092 |
OC, CC, EC | ARQ 092 + paclitaxel or ARQ 092 + anastrozole | NCT02476955 |
PI3K inhibition | Copanlisib Hydrochloride | CC, OC, EC | Patients with a PI3K or a PTEN mutation receive copanlisib | NCT02465060 |
GSK2636771 | CC, OC, EC | Patients with a PTEN mutation/expression/loss | NCT02465060 | |
Dual PI3K/mTOR inhibition | Gedatolisib PF-05212384 |
EC and other solid tumors | Single experimental arm: palbociclib and gedatolisib | NCT03065062 |
mTORC1/2 vs. AKT inhibition | vistusertib AZD2014 vs. capivasertib AZD5363 |
Recurrent EC or OC | (olaparib, vistusertib) vs. (olaparib, capivasertib) |
NCT02208375 |
Dual Akt/ERK inhibition | ONC201 | Recurrent or metastatic EC |
Single experimental arm: ONC201 treatment | NCT03099499 |
* accurate data as of 3rd January 2020. Abbreviations: EC: endometrial cancer, OC: ovarian cancer, CC: cervical cancer, HR: hormone receptor; mTORC1: mammalian target of rapamycin complex 1, AKT: protein kinase B, PI3K: Phosphoinositide 3-kinase, mTOR: mammalian target of rapamycin.